Down-regulation	O
of	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:	O
524	O
]	O

The	O
effect	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
proteins	O
was	O
examined	O
in	O
in	B-cell_line
vitro	I-cell_line
activated	I-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
by	O
Western	O
blot	O
analysis	O
.	O

Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
,	O
p50	B-protein
,	O
and	O
its	O
precursor	O
,	O
p105	B-protein
,	O
was	O
increased	O
progressively	O
.	O

When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	B-protein
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O

Besides	O
p50	B-protein
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
,	O
namely	O
c-rel	B-protein
.	O

In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	B-protein
DNA-protein	I-protein
complex	I-protein
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
.	O

Further	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
construct	B-DNA
containing	O
four	O
tandem	B-DNA
repeats	I-DNA
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
of	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

92	NULL
,	NULL
lpp	NULL
10990-10994	NULL
,	NULL
November	NULL
1995	NULL
Immunology	NULL
Down-regulation	NULL
of	NULL
NF-B	NULL
protein	NULL
levels	NULL
in	NULL
activated	NULL
human	NULL
lymphocytes	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D3	NULL
(	NULL
transcription	NULL
factors	NULL
/vitamin	NULL
proteins	NULL
)	NULL
XIAO-PENG	NULL
YU	NULL
,	NULL
TEREsITA	NULL
BELLIDO	NULL
,	NULL
AND	NULL
STAVROS	NULL
C.	NULL
ManoLaGas*	NULL
Division	NULL
of	NULL
Endocrinology	NULL
and	NULL
Metabolism	NULL
,	NULL
Center	NULL
for	NULL
Osteoporosis	NULL
and	NULL
Metabolic	NULL
Bone	NULL
Diseases	NULL
,	NULL
University	NULL
of	NULL
Arkansas	NULL
for	NULL
Medical	NULL
Sciences	NULL
,	NULL
Little	NULL
Rock	NULL
,	NULL
AR	NULL
72205	NULL
Communicated	NULL
by	NULL
H.	NULL
F.	NULL
DeLuca	NULL
,	NULL
University	NULL
of	NULL
Wisconsin	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
July	NULL
19	NULL
,	NULL
1995	NULL
ABSTRACT	NULL
The	NULL
effect	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
]	NULL
,	NULL
a	NULL
steroid	NULL
hormone	NULL
with	NULL
immunomodulating	NULL
properties	NULL
,	NULL
on	NULL
nuclear	NULL
factor	NULL
xB	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
proteins	NULL
was	NULL
examined	NULL
in	NULL
in	NULL
vitro	NULL
activated	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Over	NULL
a	NULL
72-hr	NULL
period	NULL
of	NULL
activation	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
50-kDa	NULL
NF-xB	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
its	NULL
precursor	NULL
,	NULL
p105	NULL
,	NULL
was	NULL
increased	NULL
progressively	NULL
.	NULL

When	NULL
cells	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
mature	NULL
protein	NULL
as	NULL
well	NULL
as	NULL
its	NULL
precursor	NULL
were	NULL
decreased	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
hormone	NULL
on	NULL
the	NULL
levels	NULL
of	NULL
p50	NULL
was	NULL
demonstrable	NULL
in	NULL
the	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
compartments	NULL
;	NULL
it	NULL
required	NULL
between	NULL
4	NULL
and	NULL
8	NULL
hr	NULL
and	NULL
was	NULL
specific	NULL
,	NULL
as	NULL
25-hydroxyvitamin	NULL
D	NULL
;	NULL
and	NULL
24,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
were	NULL
ineffective	NULL
.	NULL

Besides	NULL
p50	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
levels	NULL
of	NULL
another	NULL
NF-xB	NULL
protein	NULL
,	NULL
namely	NULL
c-rel	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
abundance	NULL
of	NULL
a	NULL
specific	NULL
DNA-protein	NULL
complex	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
lymphocytes	NULL
with	NULL
a	NULL
labeled	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
motif	NULL
.	NULL

Further	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-B	NULL
in	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
containing	NULL
four	NULL
tandem	NULL
repeats	NULL
of	NULL
the	NULL
NF-B	NULL
binding	NULL
sequence	NULL
of	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
reporter	NULL
gene	NULL
.	NULL

These	NULL
observations	NULL
demonstrate	NULL
directly	NULL
that	NULL
there	NULL
is	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
NF-KB	NULL
during	NULL
human	NULL
lymphocyte	NULL
activation	NULL
and	NULL
suggest	NULL
that	NULL
this	NULL
process	NULL
is	NULL
hormonally	NULL
regulated	NULL
.	NULL

Besides	NULL
its	NULL
role	NULL
in	NULL
calcium	NULL
and	NULL
skeletal	NULL
homeostasis	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D3	NULL
]	NULL
plays	NULL
a	NULL
widespread	NULL
role	NULL
in	NULL
the	NULL
differentiation	NULL
,	NULL
proliferation	NULL
,	NULL
biosynthetic	NULL
activity	NULL
,	NULL
and	NULL
function	NULL
of	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Its	NULL
effects	NULL
on	NULL
lymphocytes	NULL
are	NULL
mediated	NULL
by	NULL
the	NULL
specific	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
recep-tor	NULL
,	NULL
a	NULL
ligand-dependent	NULL
transcription	NULL
factor	NULL
that	NULL
recognizes	NULL
DNA	NULL
elements	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
its	NULL
target	NULL
genes	NULL
,	NULL
termed	NULL
vitamin	NULL
D	NULL
response	NULL
elements	NULL
(	NULL
VDREs	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
VDREs	NULL
are	NULL
not	NULL
present	NULL
in	NULL
the	NULL
regulatory	NULL
sequences	NULL
of	NULL
genes	NULL
influenced	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
lymphocytes	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
lymphocytes	NULL
are	NULL
pleiotropic	NULL
and	NULL
depend	NULL
on	NULL
the	NULL
mode	NULL
of	NULL
activation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
considerations	NULL
,	NULL
we	NULL
have	NULL
hypothesized	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
exerts	NULL
its	NULL
actions	NULL
on	NULL
lymphocyte	NULL
products	NULL
through	NULL
interactions	NULL
with	NULL
other	NULL
factors	NULL
generated	NULL
following	NULL
activation	NULL
,	NULL
rather	NULL
than	NULL
through	NULL
direct	NULL
interaction	NULL
of	NULL
its	NULL
receptor	NULL
with	NULL
these	NULL
genes	NULL
.	NULL

A	NULL
precedent	NULL
for	NULL
modulation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
a	NULL
steroid	NULL
hormone	NULL
through	NULL
influencing	NULL
other	NULL
transcription	NULL
factors	NULL
has	NULL
been	NULL
set	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-kB	NULL
)	NULL
designates	NULL
a	NULL
family	NULL
of	NULL
structurally	NULL
and	NULL
functionally	NULL
related	NULL
protein	NULL
complexes	NULL
used	NULL
by	NULL
lymphoid	NULL
cells	NULL
to	NULL
regulate	NULL
genes	NULL
encoding	NULL
products	NULL
that	NULL
participate	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
4	NULL
)	NULL
.	NULL

All	NULL
members	NULL
of	NULL
the	NULL
family	NULL
share	NULL
a	NULL
300-amino	NULL
acid	NULL
region	NULL
of	NULL
homology	NULL
that	NULL
mediates	NULL
dimerization	NULL
and	NULL
high-affinity	NULL
binding	NULL
to	NULL
decameric	NULL
DNA	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

10990	NULL
sequences	NULL
of	NULL
the	NULL
consensus	NULL
5-GGGRNNYYCC-3	NULL
'	NULL
(	NULL
where	NULL
R	NULL
is	NULL
purine	NULL
and	NULL
Y	NULL
is	NULL
pyrimidine	NULL
)	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
NF-KB	NULL
to	NULL
bind	NULL
DNA	NULL
is	NULL
controlled	NULL
by	NULL
protein-protein	NULL
interactions	NULL
with	NULL
highly	NULL
specific	NULL
inhibitor	NULL
proteins	NULL
,	NULL
termed	NULL
IxB	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Association	NULL
with	NULL
IxB	NULL
prevents	NULL
nuclear	NULL
uptake	NULL
by	NULL
retaining	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

Stimulation	NULL
with	NULL
various	NULL
agents	NULL
causes	NULL
the	NULL
release	NULL
of	NULL
IxB	NULL
from	NULL
the	NULL
rel-NF-	NULL
«	NULL
B	NULL
complexes	NULL
,	NULL
thus	NULL
allowing	NULL
the	NULL
rapid	NULL
translocation	NULL
of	NULL
rel-NF-	NULL
«	NULL
B	NULL
into	NULL
the	NULL
nucleus	NULL
.	NULL

The	NULL
prototypical	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
composed	NULL
of	NULL
two	NULL
distinct	NULL
subunits	NULL
of	NULL
50	NULL
kDa	NULL
and	NULL
65	NULL
kDa	NULL
referred	NULL
to	NULL
as	NULL
p50	NULL
and	NULL
p65	NULL
or	NULL
RelA	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
p50	NULL
subunit	NULL
is	NULL
synthesized	NULL
as	NULL
a	NULL
105-kDa	NULL
protein	NULL
,	NULL
p105	NULL
,	NULL
that	NULL
undergoes	NULL
posttranslational	NULL
processing	NULL
to	NULL
the	NULL
mature	NULL
form	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

c-rel	NULL
,	NULL
the	NULL
normal	NULL
cellular	NULL
homolog	NULL
of	NULL
the	NULL
oncogene	NULL
product	NULL
of	NULL
the	NULL
avian	NULL
reticuloendotheliosis	NULL
virus	NULL
REV-T	NULL
v-rel	NULL
,	NULL
is	NULL
another	NULL
member	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
in	NULL
mammalian	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

p50	NULL
,	NULL
c-rel	NULL
,	NULL
and	NULL
p65	NULL
are	NULL
in	NULL
fact	NULL
the	NULL
major	NULL
components	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
,	NULL
binding	NULL
to	NULL
most	NULL
of	NULL
the	NULL
identified	NULL
cis-acting	NULL
«	NULL
B	NULL
sites	NULL
.	NULL

All	NULL
these	NULL
proteins	NULL
are	NULL
expressed	NULL
in	NULL
various	NULL
cells	NULL
,	NULL
but	NULL
most	NULL
abundantly	NULL
in	NULL
differentiated	NULL
human	NULL
lymphoid	NULL
cell	NULL
lines	NULL
and	NULL
human	NULL
peripheral	NULL
blood	NULL
resting	NULL
B	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Though	NULL
all	NULL
of	NULL
them	NULL
are	NULL
constitutively	NULL
expressed	NULL
,	NULL
their	NULL
expression	NULL
is	NULL
up-regulated	NULL
by	NULL
NF-	NULL
«	NULL
B-activated	NULL
conditions	NULL
such	NULL
as	NULL
those	NULL
occurring	NULL
during	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
or	NULL
B	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Control	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
preexisting	NULL
forms	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
attracted	NULL
large	NULL
attention	NULL
.	NULL

However	NULL
,	NULL
relatively	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
various	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
themselves	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
indicating	NULL
that	NULL
during	NULL
normal	NULL
T-cell	NULL
activation	NULL
in	NULL
vitro	NULL
,	NULL
there	NULL
is	NULL
a	NULL
progressive	NULL
increase	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
p50	NULL
,	NULL
its	NULL
p105	NULL
precursor	NULL
,	NULL
and	NULL
c-rel	NULL
and	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
acts	NULL
to	NULL
down-regulate	NULL
the	NULL
levels	NULL
of	NULL
these	NULL
proteins	NULL
and	NULL
thereby	NULL
decrease	NULL
their	NULL
transcriptional	NULL
activity	NULL
in	NULL
human	NULL
lymphocytes	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Materials	NULL
.	NULL

'*5I-labeled	NULL
protein	NULL
A	NULL
(	NULL
30	NULL
mCi/mg	NULL
;	NULL
1	NULL
Ci	NULL
=	NULL
37	NULL
GBq	NULL
)	NULL
,	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
JATP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
)	NULL
,	NULL
and	NULL
D-	NULL
[	NULL
dichloroacetyl-i-'4C	NULL
)	NULL
chloramphenicol	NULL
(	NULL
50-60	NULL
mCi/mmol	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Amersham	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds3	NULL
,	NULL
24,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
[	NULL
24,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
}	NULL
,	NULL
and	NULL
25-hydroxyvitamin	NULL
D	NULL
;	NULL
[	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
:	NULL
]	NULL
)	NULL
were	NULL
gifts	NULL
from	NULL
Milan	NULL
Uskokovic	NULL
(	NULL
Hoffmann-LaRoche	NULL
)	NULL
.	NULL

Phytohe-magglutinin	NULL
(	NULL
PHA	NULL
)	NULL
and	NULL
triamcinolone	NULL
acetonide	NULL
(	NULL
TRM	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

The	NULL
OKT3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Ab	NULL
)	NULL
to	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
was	NULL
generated	NULL
from	NULL
the	NULL
ATCC-CRL	NULL
8001	NULL
hybridoma	NULL
cells	NULL
.	NULL

Antisera	NULL
to	NULL
rel-related	NULL
proteins	NULL
developed	NULL
in	NULL
rabbits	NULL
were	NULL
provided	NULL
by	NULL
Nancy	NULL
Rice	NULL
(	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Anti-SP1157	NULL
rec-	NULL
Abbreviations	NULL
:	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
;	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
Ds	NULL
;	NULL
24,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D3	NULL
,	NULL
24,25-dihydroxyvitamin	NULL
Ds	NULL
;	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
,	NULL
25-hydroxyvitamin	NULL
Ds	NULL
;	NULL
TRM	NULL
,	NULL
triamcinolone	NULL
acetonide	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethyisul-fonyl	NULL
fluoride	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
Ab	NULL
,	NULL
antibody	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Immunology	NULL
:	NULL
Yu	NULL
et	NULL
al	NULL
.	NULL

ognizes	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
it	NULL
also	NULL
reacts	NULL
with	NULL
the	NULL
precursor	NULL
of	NULL
this	NULL
protein	NULL
,	NULL
p105	NULL
;	NULL
anti-SP265	NULL
recognizes	NULL
the	NULL
extreme	NULL
C	NULL
terminus	NULL
of	NULL
the	NULL
75-kDa	NULL
c-rel	NULL
protein	NULL
.	NULL

The	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
plasmid	NULL
,	NULL
p	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
4-CAT	NULL
,	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
four	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sequence	NULL
(	NULL
5'-gatcCAGAGGGGACTTT-TCCGAGA-3	NULL
'	NULL
)	NULL
of	NULL
the	NULL
immunoglobulin	NULL
«	NULL
light	NULL
chain	NULL
gene	NULL
at	NULL
a	NULL
BamHI	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
of	NULL
pE1BTATA-CAT	NULL
(	NULL
14	NULL
)	NULL
and	NULL
was	NULL
provided	NULL
by	NULL
Michael	NULL
Su	NULL
(	NULL
Vertex	NULL
Pharmaceuticals	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Cells	NULL
and	NULL
Culture	NULL
Conditions	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
from	NULL
normal	NULL
volunteers	NULL
or	NULL
buffy	NULL
coats	NULL
were	NULL
isolated	NULL
by	NULL
Ficoll/Hypaque	NULL
(	NULL
15	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
2	NULL
ug/ml	NULL
)	NULL
,	NULL
with	NULL
OKT3	NULL
(	NULL
1:250	NULL
dilution	NULL
)	NULL
,	NULL
or	NULL
with	NULL
other	NULL
reagents	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
human	NULL
T-cell	NULL
leukemia	NULL
cell	NULL
line	NULL
Jurkat	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
and	NULL
anti-biotics	NULL
.	NULL

Preparation	NULL
of	NULL
Subcellular	NULL
Fractions	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
resuspended	NULL
at	NULL
4°C	NULL
in	NULL
10	NULL
mM	NULL
TrisHCl	NULL
,	NULL
pH	NULL
7.4/1.5	NULL
mM	NULL
EDTA/5	NULL
mM	NULL
dithiothreitol/1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
/0.3	NULL
M	NULL
KCI	NULL
,	NULL
and	NULL
sonicated	NULL
.	NULL

Cytosol	NULL
fractions	NULL
were	NULL
obtained	NULL
by	NULL
centrifugation	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
105,000	NULL
x	NULL
g	NULL
and	NULL
precipitated	NULL
with	NULL
ammonium	NULL
sulfate	NULL
(	NULL
40	NULL
%	NULL
of	NULL
saturation	NULL
)	NULL
.	NULL

Peliets	NULL
were	NULL
collected	NULL
and	NULL
solubilized	NULL
in	NULL
10	NULL
mM	NULL
TrisHCl	NULL
,	NULL
pH	NULL
7.4/1.5	NULL
mM	NULL
EDTA/5	NULL
mM	NULL
dithiothreitol/1	NULL
mM	NULL
PMSF	NULL
.	NULL

For	NULL
the	NULL
experiments	NULL
in	NULL
which	NULL
we	NULL
used	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
or	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
isolation	NULL
of	NULL
nuclear	NULL
fractions	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

All	NULL
buffers	NULL
contained	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
1	NULL
mg	NULL
of	NULL
leupeptin	NULL
per	NULL
mi	NULL
,	NULL
0.5	NULL
mg	NULL
of	NULL
pepstatin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
1	NULL
mg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
.	NULL

Briefly	NULL
,	NULL
46	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
hypotonic	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9/1.5	NULL
mM	NULL
MgCl	NULL
;	NULL
/10	NULL
mM	NULL
KCI/0.5	NULL
mM	NULL
dithio-threitol	NULL
)	NULL
and	NULL
lysed	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
hypotonic	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
30	NULL
pl	NULL
per	NULL
10	NULL
``	NULL
cells	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
(	NULL
10,000	NULL
x	NULL
g	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Supernatants	NULL
were	NULL
collected	NULL
and	NULL
centrifuged	NULL
at	NULL
100,000	NULL
%	NULL
g	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
high-speed	NULL
supernatant	NULL
was	NULL
used	NULL
as	NULL
the	NULL
cytosolic	NULL
fraction	NULL
.	NULL

Pelleted	NULL
nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9/420	NULL
mM	NULL
NaC1/1.5	NULL
mM	NULL
MgC1	NULL
;	NULL
/0.2	NULL
mM	NULL
EDTA/25	NULL
%	NULL
glycerol	NULL
)	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Lysed	NULL
nuclei	NULL
were	NULL
dispersed	NULL
in	NULL
a	NULL
Vortex	NULL
and	NULL
centrifuged	NULL
at	NULL
10,000	NULL
x	NULL
g	NULL
,	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
;	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
snap-frozen	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Protein	NULL
concentrations	NULL
of	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
fractions	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis	NULL
.	NULL

Protein	NULL
extracts	NULL
(	NULL
100	NULL
ug	NULL
per	NULL
lane	NULL
)	NULL
were	NULL
electrophoresed	NULL
on	NULL
SDS/polyacrylamide	NULL
(	NULL
7.5	NULL
%	NULL
)	NULL
gels	NULL
(	NULL
18	NULL
)	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
as	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Radioactivity	NULL
of	NULL
the	NULL
bands	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
B	NULL
scanner	NULL
(	NULL
AMBIS	NULL
Systems	NULL
)	NULL
.	NULL

Background	NULL
was	NULL
subtracted	NULL
from	NULL
each	NULL
lane	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
lymphocytes	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
.	NULL

A	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-kB	NULL
binding	NULL
sequence	NULL
of	NULL
the	NULL
human	NULL
interleukin	NULL
6	NULL
(	NULL
IL-6	NULL
)	NULL
promoter	NULL
(	NULL
-82	NULL
bp	NULL
to	NULL
-47	NULL
bp	NULL
,	NULL
5S	NULL
!	NULL

-ATCAAATGTGGGATTTTCCCAT-GAGTCTCAATATTA-3	NULL
'	NULL
)	NULL
was	NULL
end-labeled	NULL
using	NULL
[	NULL
y-	NULL
>	NULL
``	NULL
P	NULL
]	NULL
ATP	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

One	NULL
nanogram	NULL
of	NULL
end-labeled	NULL
probe	NULL
was	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
pg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
ug	NULL
of	NULL
double-stranded	NULL
salmon	NULL
sperm	NULL
DNA	NULL
per	NULL
ml	NULL
,	NULL
6	NULL
%	NULL
glycerol	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
80	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EGTA	NULL
.	NULL

Competition	NULL
studies	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
nuclear	NULL
extracts	NULL
with	NULL
unlabeled	NULL
NF-KB	NULL
oligonucleotide	NULL
or	NULL
a	NULL
22-mer	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
AP-1	NULL
binding	NULL
motif	NULL
(	NULL
5-CTAGTGATGAGTCAGCCGG	NULL
ATC-3	NULL
'	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
-	NULL
10991	NULL
5	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
30-min	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
on	NULL
native	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Transfection	NULL
and	NULL
CAT	NULL
Assay	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
0.05	NULL
M	NULL
TrisHCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
0.25	NULL
mg	NULL
of	NULL
DEAE-dextran	NULL
per	NULL
ml	NULL
(	NULL
Phar-macia	NULL
)	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
p	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
,	NULL
-CAT	NULL
plasmid	NULL
or	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
(	NULL
pRSV-CAT	NULL
)	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

After	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
diluted	NULL
with	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
pelleted	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
10~®	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
2D	NULL
;	NULL
for	NULL
48	NULL
hr	NULL
,	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
2	NULL
ug/ml	NULL
)	NULL
for	NULL
the	NULL
last	NULL
8	NULL
hr	NULL
of	NULL
the	NULL
48-hr	NULL
period	NULL
,	NULL
and	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
prepared	NULL
by	NULL
three	NULL
cycles	NULL
of	NULL
freeze/thaw	NULL
in	NULL
0.1	NULL
M	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
.	NULL

CAT	NULL
enzyme	NULL
activity	NULL
was	NULL
assayed	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
,	NULL
and	NULL
values	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
acetylated	NULL
chlor-amphenicol	NULL
.	NULL

RESULTS	NULL
Analysis	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
NF-KB	NULL
,	NULL
prior	NULL
to	NULL
and	NULL
during	NULL
activation	NULL
of	NULL
normal	NULL
human	NULL
PBMCs	NULL
with	NULL
PHA	NULL
over	NULL
a	NULL
period	NULL
of	NULL
72	NULL
hr	NULL
,	NULL
was	NULL
performed	NULL
using	NULL
an	NULL
Ab	NULL
(	NULL
SP1157	NULL
)	NULL
recognizing	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
as	NULL
well	NULL
as	NULL
the	NULL
p105	NULL
precursor	NULL
of	NULL
this	NULL
protein	NULL
(	NULL
13	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
either	NULL
the	NULL
cytosolic	NULL
or	NULL
the	NULL
nuclear	NULL
fraction	NULL
,	NULL
p50	NULL
or	NULL
p105	NULL
was	NULL
undetectable	NULL
prior	NULL
to	NULL
or	NULL
following	NULL
12	NULL
hr	NULL
of	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
following	NULL
24	NULL
hr	NULL
of	NULL
activation	NULL
,	NULL
the	NULL
p50	NULL
was	NULL
detected	NULL
in	NULL
both	NULL
fractions	NULL
.	NULL

Thereafter	NULL
,	NULL
its	NULL
expression	NULL
increased	NULL
progressively	NULL
.	NULL

Activation	NULL
also	NULL
led	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
p105	NULL
precursor	NULL
of	NULL
p50	NULL
in	NULL
the	NULL
cytosol	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
this	NULL
protein	NULL
increased	NULL
progressively	NULL
during	NULL
the	NULL
activation	NULL
period	NULL
.	NULL

In	NULL
this	NULL
particular	NULL
experiment	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
p105	NULL
signal	NULL
appeared	NULL
weaker	NULL
than	NULL
that	NULL
of	NULL
the	NULL
p50	NULL
;	NULL
however	NULL
,	NULL
this	NULL
was	NULL
not	NULL
a	NULL
consistent	NULL
finding	NULL
in	NULL
subsequent	NULL
experiments	NULL
.	NULL

Addition	NULL
of	NULL
10-8	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
simultaneously	NULL
with	NULL
addition	NULL
of	NULL
PHA	NULL
caused	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
p50	NULL
at	NULL
all	NULL
time	NULL
points	NULL
examined	NULL
.	NULL

A	NULL
similar	NULL
effect	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
cytosolic	NULL
and	NULL
the	NULL
nuclear	NULL
fractions	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
decreased	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
p105	NULL
precursor	NULL
of	NULL
p50	NULL
in	NULL
the	NULL
cytosolic	NULL
fraction	NULL
.	NULL

Vitamin	NULL
D	NULL
metabolites	NULL
with	NULL
lesser	NULL
potency	NULL
[	NULL
and	NULL
lower	NULL
affinity	NULL
for	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
]	NULL
had	NULL
no	NULL
appreciable	NULL
effects	NULL
on	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
NF-kB	NULL
following	NULL
a	NULL
72-hr	NULL
activation	NULL
with	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
the	NULL
synthetic	NULL
glucocorticoid	NULL
TRM	NULL
also	NULL
inhibited	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
and	NULL
that	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
p50	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
resting	NULL
cells	NULL
and	NULL
the	NULL
p105	NULL
signal	NULL
was	NULL
at	NULL
least	NULL
as	NULL
intense	NULL
as	NULL
that	NULL
Time	NULL
0	NULL
-	NULL
12hr	NULL
24hr	NULL
48	NULL
hr	NULL
72	NULL
hr	NULL
roar	NULL
Am	NULL
Ay	NULL
Ary	NULL
Ay	NULL
Cytosolic	NULL
Fraction	NULL
Nuclear	NULL
Fraction	NULL
<	NULL
-	NULL
50	NULL
kDa	NULL
1	NULL
,25	NULL
(	NULL
OH	NULL
)	NULL
203	NULL
ie	NULL
#	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

Effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
in	NULL
PHA-activated	NULL
human	NULL
lymphocytes	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
with	NULL
PHA	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~8	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
collected	NULL
at	NULL
different	NULL
times	NULL
after	NULL
activation	NULL
;	NULL
subcellular	NULL
fractions	NULL
were	NULL
then	NULL
prepared	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
antibody	NULL
SP1157	NULL
.	NULL

10992	NULL
-	NULL
Immunology	NULL
:	NULL
Yu	NULL
et	NULL
al	NULL
.	NULL

PHA	NULL
PHA	NULL
PHA	NULL
PHA	NULL
Resting	NULL
+	NULL
+	NULL
+	NULL
+	NULL
PBMC	NULL
PHA	NULL
1,25	NULL
D3	NULL
25	NULL
D3	NULL
24,2503	NULL
TRM	NULL
<	NULL
€-	NULL
105	NULL
kDa	NULL
A	NULL
as-	NULL
Uy	NULL
a	NULL
p	NULL
<	NULL
50	NULL
kDa	NULL
46	NULL
>	NULL
sae	NULL
4,000	NULL
|-	NULL
[	NULL
_	NULL
]	NULL
105	NULL
koa	NULL
©	NULL
3.000	NULL
|-77	NULL
)	NULL
so	NULL
oa	NULL
2,000	NULL
|-a	NULL
o	NULL
-L	NULL
§	NULL
2	NULL
(	NULL
2	NULL
0	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Steroid	NULL
specificity	NULL
of	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
PHA-activated	NULL
human	NULL
lymphocytes	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
for	NULL
72	NULL
hr	NULL
without	NULL
stimuli	NULL
or	NULL
with	NULL
PHA	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10-8	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
Ds	NULL
,	NULL
24,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D3	NULL
,	NULL
or	NULL
TRM	NULL
.	NULL

Western	NULL
blotting	NULL
of	NULL
cytosolic	NULL
proteins	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
SP1157	NULL
antibody	NULL
.	NULL

Bars	NULL
represent	NULL
radioactivity	NULL
per	NULL
band	NULL
.	NULL

Positions	NULL
of	NULL
molecular	NULL
mass	NULL
standards	NULL
are	NULL
indicated	NULL
at	NULL
the	NULL
left	NULL
.	NULL

of	NULL
p50	NULL
.	NULL

Since	NULL
in	NULL
each	NULL
experiment	NULL
we	NULL
have	NULL
utilized	NULL
PBMCs	NULL
from	NULL
a	NULL
different	NULL
donor	NULL
,	NULL
we	NULL
think	NULL
that	NULL
this	NULL
apparent	NULL
difference	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
a	NULL
difference	NULL
either	NULL
in	NULL
the	NULL
number	NULL
of	NULL
already	NULL
activated	NULL
(	NULL
in	NULL
vivo	NULL
)	NULL
lymphocytes	NULL
or	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
constitutive	NULL
expression	NULL
of	NULL
these	NULL
proteins	NULL
among	NULL
various	NULL
subjects	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
time	NULL
required	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
exert	NULL
its	NULL
inhibitory	NULL
effect	NULL
on	NULL
p50	NULL
and	NULL
p105	NULL
,	NULL
PBMCs	NULL
were	NULL
activated	NULL
for	NULL
72	NULL
hr	NULL
with	NULL
PHA	NULL
,	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
added	NULL
either	NULL
simultaneously	NULL
with	NULL
addition	NULL
of	NULL
PHA	NULL
or	NULL
24	NULL
,	NULL
48	NULL
,	NULL
64	NULL
,	NULL
68	NULL
,	NULL
or	NULL
70	NULL
hr	NULL
following	NULL
addition	NULL
of	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
inhibiting	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
p50	NULL
and	NULL
p105	NULL
was	NULL
apparent	NULL
when	NULL
the	NULL
hormone	NULL
was	NULL
added	NULL
simultaneously	NULL
with	NULL
PHA	NULL
or	NULL
24	NULL
,	NULL
48	NULL
,	NULL
or	NULL
64	NULL
hr	NULL
following	NULL
addition	NULL
of	NULL
PHA	NULL
.	NULL

However	NULL
,	NULL
when	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
added	NULL
into	NULL
the	NULL
culture	NULL
for	NULL
the	NULL
last	NULL
4	NULL
hr	NULL
(	NULL
68	NULL
hr	NULL
following	NULL
PHA	NULL
activation	NULL
)	NULL
or	NULL
the	NULL
last	NULL
2	NULL
hr	NULL
(	NULL
70	NULL
hr	NULL
following	NULL
PHA	NULL
activation	NULL
)	NULL
of	NULL
the	NULL
72-hr	NULL
culture	NULL
period	NULL
,	NULL
there	NULL
was	NULL
no	NULL
discernible	NULL
effect	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
[	NULL
}	NULL
H	NULL
thy-midine	NULL
incorporation	NULL
when	NULL
it	NULL
was	NULL
added	NULL
into	NULL
the	NULL
cultures	NULL
simultaneously	NULL
with	NULL
addition	NULL
of	NULL
PHA	NULL
or	NULL
24	NULL
hr	NULL
following	NULL
the	NULL
addition	NULL
of	NULL
PHA	NULL
.	NULL

Further	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
mode	NULL
of	NULL
activation	NULL
of	NULL
lymphocytes	NULL
would	NULL
influence	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
p50/p105	NULL
and	NULL
whether	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
had	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
related	NULL
protein	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
activity-	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Cytosolic	NULL
preparations	NULL
from	NULL
stimulated	NULL
lymphocytes	NULL
contained	NULL
a	NULL
75-kDa	NULL
protein	NULL
that	NULL
reacted	NULL
with	NULL
an	NULL
Ab	NULL
recognizing	NULL
the	NULL
extreme	NULL
C	NULL
terminus	NULL
of	NULL
c-rel	NULL
(	NULL
Ab	NULL
$	NULL
P265	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
p105	NULL
and	NULL
p50	NULL
,	NULL
in	NULL
PHA-	NULL
and	NULL
OKT3-activated	NULL
cells	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
all	NULL
three	NULL
proteins	NULL
were	NULL
decreased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
an	NULL
alternative	NULL
Ab	NULL
that	NULL
recognizes	NULL
the	NULL
N	NULL
terminus	NULL
portion	NULL
of	NULL
c-rel	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
-	NULL
105	NULL
kDa	NULL
ACTIVATION	NULL
g~	NULL
150	NULL
I	NULL
T	NULL
8	NULL
oren	NULL
``	NULL
man	NULL
nese	NULL
bis	NULL
E	NULL
g	NULL
100	NULL
£	NULL
[	NULL
x	NULL
S	NULL
a	NULL
.	NULL

2	NULL
-	NULL
50	NULL
kel	NULL
&	NULL
&	NULL
.	NULL

C.	NULL
0	NULL
/F	NULL
Control	NULL
0	NULL
24	NULL
48	NULL
64	NULL
68	NULL
70	NULL
Hours	NULL
following	NULL
activation	NULL
Duration	NULL
of	NULL
Exposure	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
(	NULL
Hours	NULL
)	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Time	NULL
course	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
cell	NULL
proliferation	NULL
in	NULL
PH	NULL
A-activated	NULL
human	NULL
lymphocytes	NULL
.	NULL

PBMCs	NULL
were	NULL
activated	NULL
for	NULL
72	NULL
hr	NULL
with	NULL
PHA	NULL
,	NULL
and	NULL
1078	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
added	NULL
either	NULL
simultaneously	NULL
with	NULL
addition	NULL
of	NULL
PHA	NULL
or	NULL
24	NULL
,	NULL
48	NULL
,	NULL
64	NULL
,	NULL
68	NULL
,	NULL
or	NULL
70	NULL
hr	NULL
following	NULL
addition	NULL
of	NULL
PHA	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
72-hr	NULL
activation	NULL
,	NULL
cytosols	NULL
were	NULL
prepared	NULL
by	NULL
ultracentrifugation	NULL
,	NULL
and	NULL
aliquots	NULL
(	NULL
100	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
were	NULL
immunoblotted	NULL
with	NULL
the	NULL
SP1157	NULL
Ab	NULL
.	NULL

Cell	NULL
proliferation	NULL
was	NULL
assessed	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
triplicate	NULL
aliquots	NULL
(	NULL
0.2	NULL
X	NULL
10°	NULL
per	NULL
0.2	NULL
ml	NULL
of	NULL
medium	NULL
)	NULL
and	NULL
was	NULL
expressed	NULL
as	NULL
cpm	NULL
xX	NULL
10-3	NULL
.	NULL

The	NULL
hatched	NULL
bar	NULL
indicates	NULL
cell	NULL
proliferation	NULL
in	NULL
PBMCs	NULL
activated	NULL
for	NULL
72	NULL
hr	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
.	NULL

Unstimulated	NULL
lymphocytes	NULL
used	NULL
for	NULL
the	NULL
PHA	NULL
activation	NULL
experiment	NULL
had	NULL
no	NULL
detectable	NULL
c-rel	NULL
;	NULL
however	NULL
,	NULL
small	NULL
levels	NULL
of	NULL
c-rel	NULL
were	NULL
present	NULL
in	NULL
the	NULL
preparation	NULL
used	NULL
for	NULL
the	NULL
OKT3	NULL
activation	NULL
experiment	NULL
,	NULL
perhaps	NULL
reflecting	NULL
an	NULL
interindividual	NULL
variation	NULL
in	NULL
the	NULL
number	NULL
of	NULL
in	NULL
vivo	NULL
(	NULL
or	NULL
during	NULL
the	NULL
isolation	NULL
procedure	NULL
)	NULL
activated	NULL
cells	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
situation	NULL
we	NULL
had	NULL
observed	NULL
in	NULL
the	NULL
preparations	NULL
used	NULL
for	NULL
the	NULL
experiments	NULL
shown	NULL
in	NULL
Figs	NULL
.	NULL

1-3	NULL
.	NULL

In	NULL
any	NULL
event	NULL
,	NULL
activation	NULL
by	NULL
either	NULL
PHA	NULL
or	NULL
OKT3	NULL
led	NULL
to	NULL
a	NULL
large	NULL
increase	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
c-rel	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
p50	NULL
and	NULL
p105	NULL
proteins	NULL
.	NULL

A	NULL
B	NULL
Lig	NULL
Hus	NULL
<	NULL
105	NULL
kDa	NULL
Wik	NULL
um	NULL
<	NULL
105	NULL
kDa	NULL
€	NULL
75	NULL
kDa	NULL
€	NULL
75	NULL
kDa	NULL
€	NULL
50	NULL
kDa	NULL
wam	NULL
mn	NULL
<	NULL
50	NULL
kDa	NULL
PHA	NULL
_	NULL
-	NULL
+	NULL
+	NULL
-o	NULL
+	NULL
+	NULL
OKT3	NULL
-	NULL
+	NULL
+	NULL
+/+	NULL
1,25	NULL
D	NULL
,	NULL
-	NULL
-	NULL
+	NULL
=/	NULL
8	NULL
..	NULL
¥	NULL
125D	NULL
,	NULL
-	NULL
>	NULL
+	NULL
sat	NULL
Ab	NULL
SP265	NULL
_	NULL
Ab	NULL
SP1157	NULL
Ab	NULL
SP265	NULL
-	NULL
Ab	NULL
SP1157	NULL
FiG	NULL
.	NULL

4	NULL
.	NULL

Regulation	NULL
of	NULL
rel-related	NULL
proteins	NULL
in	NULL
activated	NULL
human	NULL
lymphocytes	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D3	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
without	NULL
stimuli	NULL
or	NULL
with	NULL
PHA	NULL
(	NULL
4	NULL
)	NULL
or	NULL
the	NULL
OKT3	NULL
monoclonal	NULL
Ab	NULL
(	NULL
B	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
10-8	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
72	NULL
hr	NULL
of	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
cytosols	NULL
were	NULL
prepared	NULL
by	NULL
ultracentrifugation	NULL
.	NULL

Immunoblotting	NULL
was	NULL
performed	NULL
with	NULL
either	NULL
the	NULL
SP265	NULL
or	NULL
SP1157	NULL
antibodies	NULL
.	NULL

Immunology	NULL
:	NULL
Yu	NULL
et	NULL
al	NULL
.	NULL

The	NULL
inhibiting	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
was	NULL
confirmed	NULL
with	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
response	NULL
element	NULL
(	NULL
from	NULL
the	NULL
human	NULL
IL-6	NULL
gene	NULL
promoter	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
cells	NULL
did	NULL
not	NULL
contain	NULL
proteins	NULL
capable	NULL
of	NULL
retarding	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
site	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
formed	NULL
a	NULL
DNA-protein	NULL
complex	NULL
that	NULL
appeared	NULL
as	NULL
a	NULL
single	NULL
retarded	NULL
band	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
caused	NULL
a	NULL
significant	NULL
reduction	NULL
in	NULL
the	NULL
DNA-protein	NULL
complex	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
decrease	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
this	NULL
band	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
could	NULL
be	NULL
competitively	NULL
inhibited	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
motif	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
but	NULL
not	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
a	NULL
nonspecific	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
AP-1	NULL
binding	NULL
motif	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

.	NULL

Finally	NULL
,	NULL
to	NULL
ascertain	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
inhibiting	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
,	NULL
we	NULL
proceeded	NULL
to	NULL
examine	NULL
whether	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
affect	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
the	NULL
T-lymphocytic	NULL
cell	NULL
line	NULL
Jurkat	NULL
[	NULL
which	NULL
expresses	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
con-stitutively-i.e	NULL
.	NULL

,	NULL
without	NULL
the	NULL
requirement	NULL
of	NULL
activation	NULL
(	NULL
20	NULL
)	NULL
with	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
regulatory	NULL
control	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
that	NULL
is	NULL
present	NULL
in	NULL
the	NULL
immunoglobulin	NULL
«	NULL
light	NULL
chain	NULL
gene	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
Jurkat	NULL
cells	NULL
for	NULL
8	NULL
hr	NULL
with	NULL
PHA	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B-driven	NULL
CAT	NULL
expression	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
partially	NULL
inhibited	NULL
(	NULL
39	NULL
%	NULL
+	NULL
14	NULL
%	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
(	NULL
41	NULL
%	NULL
+	NULL
5	NULL
%	NULL
inhibition	NULL
as	NULL
compared	NULL
to	NULL
untreated	NULL
cells	NULL
)	NULL
were	NULL
obtained	NULL
in	NULL
a	NULL
separate	NULL
experiment	NULL
.	NULL

é	NULL
”	NULL
PHA	NULL
PHA	NULL
PHA	NULL
PHA	NULL
PHA	NULL
©	NULL
+	NULL
g	NULL
1,25D	NULL
,	NULL
Extract	NULL
€	NULL
S	NULL
<	NULL
£	NULL
NF-KB	NULL
_	NULL
AP-	NULL
&	NULL
-	NULL
-	NULL
-	NULL
``	NULL
s	NULL
10x	NULL
40x	NULL
``	NULL
Competitor	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
2D	NULL
;	NULL
decreases	NULL
NF-	NULL
«	NULL
B-DNA	NULL
binding	NULL
activity	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
without	NULL
or	NULL
with	NULL
PHA	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10-8	NULL
M	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
for	NULL
72	NULL
hr	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
incubation	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
using	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
resting	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PHA-activated	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5-7	NULL
)	NULL
,	NULL
or	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
5-7	NULL
,	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
excess	NULL
of	NULL
unlabeled	NULL
DNAs	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
-	NULL
10993	NULL
Transfected	NULL
_	NULL
RSV	NULL
|	NULL
--	NULL
(	NULL
nF-	NULL
«	NULL
B	NULL
)	NULL
..cat	NULL
--	NULL
DNA	NULL
CAT	NULL
PHA	NULL
(	NULL
Iug/imi	NULL
)	NULL
-	NULL
-	NULL
-	NULL
-	NULL
4+	NULL
++	NULL
tasiouppb	NULL
,	NULL
-	NULL
'	NULL
=	NULL
``	NULL
=	NULL
``	NULL
C	NULL
(	NULL
10°M	NULL
)	NULL
CAT	NULL
activity	NULL
(	NULL
fold	NULL
change	NULL
)	NULL
N	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
regulatory	NULL
sequence-driven	NULL
transcription	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
p	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
4-CAT	NULL
plasmid	NULL
using	NULL
the	NULL
DEAE-dextran-mediated	NULL
transfection	NULL
method	NULL
.	NULL

After	NULL
transfection	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
10-8	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
for	NULL
48	NULL
hr	NULL
and	NULL
stimulated	NULL
with	NULL
PHA	NULL
for	NULL
the	NULL
last	NULL
8	NULL
hr	NULL
of	NULL
the	NULL
48-hr	NULL
period	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
present	NULL
in	NULL
100	NULL
ug	NULL
of	NULL
cellular	NULL
protein	NULL
was	NULL
determined	NULL
as	NULL
percentage	NULL
of	NULL
acetylated	NULL
[	NULL
!	NULL

*C	NULL
)	NULL
Jchloramphenicol	NULL
.	NULL

CAT	NULL
activity	NULL
of	NULL
the	NULL
control	NULL
group	NULL
was	NULL
designated	NULL
as	NULL
1	NULL
%	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

CAT	NULL
activity	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV-CAT	NULL
)	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

Treatment	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
48	NULL
hr	NULL
had	NULL
no	NULL
appreciable	NULL
effect	NULL
on	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
by	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
but	NULL
caused	NULL
an	NULL
~40	NULL
%	NULL
inhibition	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PHA	NULL
.	NULL

DISCUSSION	NULL
These	NULL
studies	NULL
demonstrate	NULL
that	NULL
the	NULL
abundance	NULL
of	NULL
p50	NULL
,	NULL
as	NULL
well	NULL
as	NULL
its	NULL
p105	NULL
precursor	NULL
,	NULL
and	NULL
c-rel	NULL
increase	NULL
progressively	NULL
during	NULL
prolonged	NULL
lymphocyte	NULL
activation	NULL
and	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
down-regulates	NULL
these	NULL
phenomena	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
shown	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
mRNA	NULL
of	NULL
genes	NULL
encoding	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
,	NULL
including	NULL
the	NULL
p50	NULL
and	NULL
c-rel	NULL
,	NULL
are	NULL
enhanced	NULL
in	NULL
response	NULL
to	NULL
external	NULL
stimuli	NULL
such	NULL
as	NULL
antigens	NULL
,	NULL
cytokines	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
and	NULL
lectins	NULL
(	NULL
8	NULL
,	NULL
21-24	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
observations	NULL
by	NULL
Hohmann	NULL
et	NULL
al	NULL
.	NULL

(	NULL
25	NULL
)	NULL
had	NULL
suggested	NULL
that	NULL
in	NULL
lymphocytes	NULL
and	NULL
monocytic	NULL
cells	NULL
,	NULL
preexisting	NULL
NF-kB	NULL
might	NULL
be	NULL
exhausted	NULL
and	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
be	NULL
obtained	NULL
by	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
this	NULL
paper	NULL
represent	NULL
a	NULL
direct	NULL
demonstration	NULL
of	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
during	NULL
normal	NULL
lymphocyte	NULL
activation	NULL
and	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
these	NULL
earlier	NULL
obser-vations	NULL
.	NULL

Our	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
inhibiting	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
due	NULL
to	NULL
interference	NULL
with	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

This	NULL
contention	NULL
is	NULL
supported	NULL
by	NULL
several	NULL
pieces	NULL
of	NULL
evidence	NULL
.	NULL

(	NULL
i	NULL
)	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
levels	NULL
of	NULL
not	NULL
only	NULL
p50	NULL
but	NULL
also	NULL
its	NULL
p105	NULL
precursor	NULL
.	NULL

(	NULL
#	NULL
)	NULL
Protein	NULL
levels	NULL
continued	NULL
to	NULL
show	NULL
an	NULL
increasing	NULL
trend	NULL
with	NULL
time	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D3	NULL
,	NULL
albeit	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
.	NULL

(	NULL
i	NULL
?	NULL
)	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
the	NULL
levels	NULL
of	NULL
p50	NULL
in	NULL
the	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
compartments-hence	NULL
,	NULL
excluding	NULL
a	NULL
mere	NULL
effect	NULL
of	NULL
the	NULL
hormone	NULL
on	NULL
the	NULL
translocation	NULL
of	NULL
the	NULL
protein	NULL
between	NULL
different	NULL
cell	NULL
compartments	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
evidence	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
synthesis	NULL
,	NULL
we	NULL
found	NULL
that	NULL
nuclear	NULL
extracts	NULL
from	NULL
10994	NULL
_	NULL
Immunology	NULL
:	NULL
Yu	NULL
et	NULL
al	NULL
.	NULL

human	NULL
lymphocytes	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
exhibited	NULL
significantly	NULL
less	NULL
binding	NULL
to	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
motif	NULL
compared	NULL
to	NULL
lymphocytes	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
hormone	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
inhibiting	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
synthesis	NULL
is	NULL
of	NULL
functional	NULL
relevance	NULL
to	NULL
NF-	NULL
«	NULL
B-driven	NULL
transcription	NULL
.	NULL

Indeed	NULL
,	NULL
activation	NULL
of	NULL
lymphocytes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
caused	NULL
inhibition	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
minimal	NULL
promoter	NULL
consisting	NULL
of	NULL
four	NULL
tandem	NULL
repeats	NULL
of	NULL
the	NULL
NF-KB	NULL
consensus	NULL
sequence	NULL
.	NULL

By	NULL
virtue	NULL
of	NULL
the	NULL
structure	NULL
of	NULL
this	NULL
artificial	NULL
promoter	NULL
,	NULL
its	NULL
transcriptional	NULL
activity	NULL
can	NULL
be	NULL
regulated	NULL
only	NULL
by	NULL
proteins	NULL
that	NULL
recognize	NULL
this	NULL
consensus	NULL
sequence	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
evident	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D	NULL
;	NULL
must	NULL
have	NULL
exerted	NULL
its	NULL
inhibiting	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
promoter	NULL
by	NULL
decreasing	NULL
the	NULL
levels	NULL
of	NULL
such	NULL
proteins	NULL
induced	NULL
following	NULL
lymphocyte	NULL
activation	NULL
rather	NULL
than	NULL
through	NULL
a	NULL
direct	NULL
interaction	NULL
of	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
with	NULL
this	NULL
DNA	NULL
segment	NULL
.	NULL

The	NULL
rank	NULL
of	NULL
potency	NULL
of	NULL
vitamin	NULL
D	NULL
metabolites	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
-D	NULL
;	NULL
being	NULL
most	NULL
effective	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
the	NULL
promoter	NULL
studies	NULL
of	NULL
Fig	NULL
.	NULL

6	NULL
support	NULL
the	NULL
view	NULL
that	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
mediates	NULL
the	NULL
effects	NULL
seen	NULL
here	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
required	NULL
at	NULL
least	NULL
4	NULL
hr	NULL
.	NULL

Nonetheless	NULL
,	NULL
studies	NULL
involving	NULL
specific	NULL
antibodies	NULL
to	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
will	NULL
be	NULL
required	NULL
to	NULL
prove	NULL
the	NULL
hypothesis	NULL
that	NULL
this	NULL
protein	NULL
mediates	NULL
these	NULL
effects	NULL
.	NULL

In	NULL
preliminary	NULL
studies	NULL
addressing	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
synthesis	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreases	NULL
the	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
of	NULL
the	NULL
4.4-kb	NULL
transcript	NULL
of	NULL
p50	NULL
(	NULL
26	NULL
)	NULL
.	NULL

However	NULL
,	NULL
using	NULL
PBMCs	NULL
from	NULL
different	NULL
subjects	NULL
,	NULL
we	NULL
have	NULL
found	NULL
variations	NULL
on	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
effect	NULL
at	NULL
the	NULL
mRNA	NULL
abundance	NULL
level	NULL
.	NULL

These	NULL
and	NULL
related	NULL
observations	NULL
suggest	NULL
a	NULL
very	NULL
complicated	NULL
mechanism	NULL
of	NULL
action	NULL
that	NULL
may	NULL
involve	NULL
actions	NULL
at	NULL
the	NULL
transcriptional	NULL
,	NULL
translational	NULL
,	NULL
and	NULL
posttranslational	NULL
levels	NULL
as	NULL
well	NULL
as	NULL
at	NULL
the	NULL
level	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
p50	NULL
and	NULL
its	NULL
inhibitor	NULL
,	NULL
IxB	NULL
,	NULL
by	NULL
affecting	NULL
phosphorylation	NULL
of	NULL
the	NULL
latter	NULL
protein	NULL
.	NULL

The	NULL
last	NULL
possibility	NULL
has	NULL
been	NULL
suggested	NULL
by	NULL
recent	NULL
studies	NULL
of	NULL
Karin	NULL
and	NULL
colleagues	NULL
(	NULL
27	NULL
)	NULL
regarding	NULL
the	NULL
mechanism	NULL
of	NULL
glucocorticosteroid	NULL
effects	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
the	NULL
IL-2	NULL
recep-tor	NULL
,	NULL
two	NULL
molecules	NULL
critical	NULL
for	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
28	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
IL-2	NULL
production	NULL
and	NULL
lymphocyte	NULL
proliferation	NULL
(	NULL
1	NULL
)	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
antiproliferative	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
could	NULL
have	NULL
been	NULL
mediated	NULL
via	NULL
the	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

However	NULL
,	NULL
the	NULL
time	NULL
courses	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
and	NULL
lymphocyte	NULL
proliferation	NULL
were	NULL
different	NULL
.	NULL

Specifically	NULL
,	NULL
whereas	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
>	NULL
D	NULL
;	NULL
could	NULL
inhibit	NULL
cell	NULL
proliferation	NULL
only	NULL
when	NULL
it	NULL
was	NULL
added	NULL
within	NULL
the	NULL
first	NULL
24	NULL
hr	NULL
following	NULL
activation	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
decreased	NULL
p50	NULL
and	NULL
p105	NULL
levels	NULL
when	NULL
added	NULL
to	NULL
the	NULL
culture	NULL
as	NULL
late	NULL
as	NULL
64	NULL
hr	NULL
following	NULL
addition	NULL
of	NULL
the	NULL
activating	NULL
agent	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
antiproliferative	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
not	NULL
the	NULL
result	NULL
of	NULL
its	NULL
effects	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

This	NULL
view	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
lymphocytes	NULL
activated	NULL
by	NULL
OKT3	NULL
(	NULL
1	NULL
)	NULL
,	NULL
even	NULL
though	NULL
(	NULL
as	NULL
shown	NULL
here	NULL
)	NULL
it	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
in	NULL
OKT3-activated	NULL
lymphocytes	NULL
.	NULL

The	NULL
relevance	NULL
of	NULL
the	NULL
inhibiting	NULL
effects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
to	NULL
the	NULL
immunoregulating	NULL
properties	NULL
of	NULL
this	NULL
hormone	NULL
is	NULL
a	NULL
matter	NULL
of	NULL
conjecture	NULL
.	NULL

Nevertheless	NULL
,	NULL
even	NULL
though	NULL
genes	NULL
encoding	NULL
NF-kB	NULL
subunits	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
lymphocytes	NULL
,	NULL
new	NULL
synthesis	NULL
of	NULL
these	NULL
subunits	NULL
would	NULL
seem	NULL
essential	NULL
to	NULL
replenish	NULL
them	NULL
,	NULL
especially	NULL
in	NULL
situations	NULL
where	NULL
they	NULL
might	NULL
be	NULL
rapidly	NULL
consumed	NULL
such	NULL
as	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Hence	NULL
,	NULL
induced	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
may	NULL
be	NULL
necessary	NULL
to	NULL
sustain	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
over	NULL
longer	NULL
periods	NULL
of	NULL
stimulation	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
based	NULL
on	NULL
evidence	NULL
from	NULL
studies	NULL
on	NULL
the	NULL
transition	NULL
from	NULL
pre-B	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
preexisting	NULL
versus	NULL
de	NULL
novo	NULL
synthesized	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
play	NULL
a	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
causative	NULL
role	NULL
in	NULL
activated	NULL
lymphocyte	NULL
function	NULL
and	NULL
in	NULL
maintaining	NULL
the	NULL
activated	NULL
state	NULL
,	NULL
respectively	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
>	NULL
D	NULL
;	NULL
receptor	NULL
(	NULL
and	NULL
therefore	NULL
responsiveness	NULL
to	NULL
this	NULL
hormone	NULL
)	NULL
is	NULL
not	NULL
expressed	NULL
until	NULL
a	NULL
few	NULL
hours	NULL
following	NULL
lymphocyte	NULL
activation	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
view	NULL
of	NULL
these	NULL
considerations	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptor	NULL
following	NULL
activation	NULL
and	NULL
the	NULL
down-regulating	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
new	NULL
synthesis	NULL
of	NULL
NF-	NULL
«	NULL
B-related	NULL
proteins	NULL
represent	NULL
a	NULL
biologic	NULL
mechanism	NULL
whereby	NULL
excessive	NULL
lymphocyte	NULL
activation	NULL
might	NULL
be	NULL
prevented	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
obtained	NULL
preliminary	NULL
evidence	NULL
that	NULL
glucocorticosteroids	NULL
,	NULL
another	NULL
class	NULL
of	NULL
steroid	NULL
hormones	NULL
with	NULL
ubiquitous	NULL
effects	NULL
in	NULL
biology	NULL
including	NULL
immunomodulating	NULL
properties	NULL
,	NULL
exert	NULL
effects	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
.	NULL

In	NULL
line	NULL
with	NULL
this	NULL
finding	NULL
,	NULL
Hass	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
glucocorticosteroids	NULL
inhibited	NULL
phorbol	NULL
12-myristate	NULL
13-acetate-induced	NULL
transient	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
mRNA	NULL
levels	NULL
in	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
steroid	NULL
hormones	NULL
with	NULL
widespread	NULL
regulatory	NULL
influences	NULL
on	NULL
a	NULL
large	NULL
variety	NULL
of	NULL
genes	NULL
might	NULL
be	NULL
exerting	NULL
part	NULL
of	NULL
their	NULL
actions	NULL
,	NULL
indirectly	NULL
,	NULL
through	NULL
their	NULL
ability	NULL
to	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Nancy	NULL
Rice	NULL
for	NULL
the	NULL
generous	NULL
provision	NULL
of	NULL
the	NULL
antibodies	NULL
,	NULL
Dr.	NULL
Michael	NULL
Su	NULL
(	NULL
Vertex	NULL
Pharmaceuticals	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
p	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
4-CAT	NULL
construct	NULL
,	NULL
and	NULL
Ms.	NULL
Niki	NULL
Barker	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
Veterans	NULL
Affairs	NULL
Merit	NULL
Review	NULL
Grant	NULL
and	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
AR41313	NULL
and	NULL
AR43003	NULL
)	NULL
.	NULL

1	NULL
.	NULL

Manolagas	NULL
,	NULL
S.C.	NULL
,	NULL
Yu	NULL
,	NULL
X.-P.	NULL
,	NULL
Girasole	NULL
,	NULL
G.	NULL
&	NULL
Bellido	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Semin	NULL
.	NULL

Nephrol	NULL
.	NULL

14	NULL
,	NULL
129-143	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Diamond	NULL
,	NULL
M.	NULL
,	NULL
Miner	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Yoshinaga	NULL
,	NULL
S.	NULL
K.	NULL
&	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
249	NULL
,	NULL
1266-1272	NULL
.	NULL

3	NULL
.	NULL

Schiile	NULL
,	NULL
R.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Symp	NULL
.	NULL

Quant	NULL
.	NULL

Biol	NULL
.	NULL

56	NULL
,	NULL
119-127	NULL
.	NULL

4	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

5	NULL
.	NULL

Grimm	NULL
,	NULL
S.	NULL
&	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

290	NULL
,	NULL
297-308	NULL
.	NULL

6	NULL
.	NULL

Sicbenlist	NULL
,	NULL
U.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
&	NULL
Brown	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
,	NULL
405-455	NULL
.	NULL

7	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Riviere	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1019-1029	NULL
.	NULL

8	NULL
.	NULL

-	NULL
Bours	NULL
,	NULL
V.	NULL
,	NULL
Villalobos	NULL
,	NULL
J.	NULL
,	NULL
Burd	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Kelly	NULL
,	NULL
K.	NULL
&	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
348	NULL
,	NULL
76-80	NULL
.	NULL

9	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

2	NULL
,	NULL
211-220	NULL
.	NULL

10	NULL
.	NULL

Brownell	NULL
,	NULL
E.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Smith	NULL
,	NULL
R.	NULL
G.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Oncogene	NULL
3	NULL
,	NULL
93-98	NULL
.	NULL

11	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
&	NULL
Gilden	NULL
,	NULL
R.	NULL
V.	NULL
(	NULL
1988	NULL
)	NULL
in	NULL
The	NULL
Oncogene	NULL
Handbook	NULL
,	NULL
eds	NULL
.	NULL

Reddy	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Skalka	NULL
,	NULL
A.	NULL
M.	NULL
&	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
Elsevier	NULL
,	NULL
Amsterdam	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

495-562	NULL
.	NULL

12	NULL
.	NULL

Kochel	NULL
,	NULL
T.	NULL
,	NULL
Mushinski	NULL
,	NULL
J.	NULL
F.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
615-626	NULL
.	NULL

13	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
MacKichan	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
243-253	NULL
.	NULL

14	NULL
.	NULL

-	NULL
Su	NULL
,	NULL
M.	NULL
S.-S.	NULL
&	NULL
Semerjian	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Transplant	NULL
.	NULL

Proc	NULL
.	NULL

23	NULL
,	NULL
2912-2915	NULL
.	NULL

15	NULL
.	NULL

Yu	NULL
,	NULL
X.	NULL
P.	NULL
,	NULL
Mocharla	NULL
,	NULL
H.	NULL
,	NULL
Hustmyer	NULL
,	NULL
F.	NULL
G.	NULL
&	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
7588-7595	NULL
.	NULL

16	NULL
.	NULL

Stylianou	NULL
,	NULL
E.	NULL
,	NULL
O'Neill	NULL
,	NULL
L	NULL
.	NULL

A.J	NULL
.	NULL

,	NULL
Rawlinson	NULL
,	NULL
L.	NULL
,	NULL
Edbrooke	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Woo	NULL
,	NULL
P.	NULL
&	NULL
Saklatvala	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
15836-15841	NULL
.	NULL

17	NULL
.	NULL

-	NULL
Bradford	NULL
,	NULL
M.	NULL
(	NULL
1976	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72	NULL
,	NULL
248-254	NULL
.	NULL

18	NULL
.	NULL

-	NULL
Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
(	NULL
1970	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
227	NULL
,	NULL
680-685	NULL
.	NULL

19.	NULL
.	NULL

Pottratz	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
Bellido	NULL
,	NULL
T.	NULL
,	NULL
Mocharla	NULL
,	NULL
H.	NULL
,	NULL
Crabb	NULL
,	NULL
D.	NULL
&	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

93	NULL
,	NULL
944-950	NULL
.	NULL

20	NULL
.	NULL

-	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Provvedini	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Endo-crinol	NULL
.	NULL

43	NULL
,	NULL
113-122	NULL
.	NULL

21	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
Didonato	NULL
,	NULL
J.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
DNA	NULL
Cell	NULL
Biol	NULL
.	NULL

11	NULL
,	NULL
523-537	NULL
.	NULL

22	NULL
.	NULL

-	NULL
Meyer	NULL
,	NULL
R.	NULL
,	NULL
Hatada	NULL
,	NULL
H.-P.	NULL
,	NULL
Hohmann	NULL
,	NULL
H.-P.	NULL
,	NULL
Haiker	NULL
,	NULL
M.	NULL
,	NULL
Bartsch	NULL
,	NULL
C.	NULL
,	NULL
Rotlisberger	NULL
,	NULL
U.	NULL
,	NULL
Lahm	NULL
,	NULL
H.-W.	NULL
,	NULL
Schlaeger	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
vanLoon	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
&	NULL
Scheidereit	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
966-970	NULL
.	NULL

23	NULL
.	NULL

Ten	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
Israel	NULL
,	NULL
N.	NULL
,	NULL
Le	NULL
,	NULL
B.	NULL
O.	NULL
,	NULL
Mattei	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Virelizier	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
&	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
195-203	NULL
.	NULL

24	NULL
.	NULL

Bull	NULL
,	NULL
P.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
&	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9	NULL
,	NULL
5239-5243	NULL
.	NULL

25	NULL
.	NULL

Hohmann	NULL
,	NULL
H.-P.	NULL
,	NULL
Remy	NULL
,	NULL
R.	NULL
,	NULL
Scheidereit	NULL
,	NULL
C.	NULL
&	NULL
vanLoon	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
259-266	NULL
.	NULL

26	NULL
.	NULL

Yu	NULL
,	NULL
X.	NULL
P.	NULL
,	NULL
Bellido	NULL
,	NULL
T.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
&	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Bone	NULL
Miner	NULL
.	NULL

Res	NULL
.	NULL

8	NULL
,	NULL
$	NULL
126	NULL
(	NULL
abstr	NULL
.	NULL
)	NULL

.	NULL

27	NULL
.	NULL

Kahn	NULL
,	NULL
A.	NULL
,	NULL
Gibbons	NULL
,	NULL
R.	NULL
,	NULL
Perkins	NULL
,	NULL
S.	NULL
&	NULL
Gazit	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Clin	NULL
.	NULL

Orthop	NULL
.	NULL

313	NULL
,	NULL
69-75	NULL
.	NULL

28	NULL
.	NULL

-	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
J.	NULL
J.-S.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

143	NULL
,	NULL
1-62	NULL
.	NULL

29	NULL
.	NULL

Hass	NULL
,	NULL
R.	NULL
,	NULL
Brach	NULL
,	NULL
M.	NULL
,	NULL
Guniji	NULL
,	NULL
H.	NULL
,	NULL
Kharbanda	NULL
,	NULL
S.	NULL
&	NULL
Kufe	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

44	NULL
,	NULL
1569-1576	NULL
.	NULL

